Gail Boudreaux
Gail Boudreaux's purchase track record
Gail Boudreaux has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 7/17/2026 | ELV | $1.00M | +14.8% | pending | — |
| 7/18/2025 | ELV | $2.44M | +26.6% | +36.7% | +10.2% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Target (TGT) in focus as sales growth and dividend outlook discussed. Recent articles note that Target's sales growth has improved its outlook and that its 3.35% dividend is being compared to peers. Analysts also consider how the latest Federal Reserve policy could influence consumer spending at retailers like Target. A new nationwide launch of Javvy Coffee's peppermint mocha at Target stores adds a fresh product offering. The stock is currently near a long‑standing support level.
Transaction History
| ELV | ▲ Buy | Open Market | 680 | $249K | 7/17/2026 | View on chart |
| ELV | ▲ Buy | Open Market | 2,045 | $753K | 7/17/2026 | View on chart |
| TGT | ▲ Buy | Grant | 2,682 | $0 | 3/11/2026 | View on chart |
| ELV | ▼ Sell | Tax Withholding | 1,736 | $493K | 3/3/2026 | View on chart |
| ELV | ▲ Buy | Grant | 16,153 | $0 | 3/2/2026 | View on chart |
| ELV | ▲ Buy | Grant | 10,527 | $0 | 3/2/2026 | View on chart |
| ELV | ▼ Sell | Tax Withholding | 6,713 | $2.0M | 3/2/2026 | View on chart |
| ELV | ▲ Buy | Open Market | 2,334 | $668K | 7/18/2025 | View on chart |
| ELV | ▲ Buy | Open Market | 5,116 | $1.5M | 7/18/2025 | View on chart |
| ELV | ▲ Buy | Open Market | 1,050 | $302K | 7/18/2025 | View on chart |
| TGT | ▲ Buy | Grant | 2,946 | $0 | 3/12/2025 | View on chart |
| ELV | ▼ Sell | Tax Withholding | 10,396 | $4.1M | 3/3/2025 | View on chart |
| ELV | ▲ Buy | Grant | 10,620 | $0 | 3/3/2025 | View on chart |
| ELV | ▲ Buy | Grant | 15,587 | $0 | 3/3/2025 | View on chart |
| ELV | ▼ Sell | Open Market | 1,100 | $548K | 7/22/2024 | View on chart |
| ELV | ▼ Sell | Open Market | 20,779 | $10.4M | 7/22/2024 | View on chart |
| ELV | ▼ Sell | Open Market | 6,621 | $3.3M | 7/22/2024 | View on chart |
| ELV | ▼ Sell | Open Market | 2,250 | $1.1M | 7/22/2024 | View on chart |
| ELV | ▼ Sell | Open Market | 1,000 | $504K | 7/22/2024 | View on chart |
| ELV | ▼ Sell | Open Market | 2,250 | $1.1M | 7/22/2024 | View on chart |
| TGT | ▲ Buy | Grant | 1,873 | $0 | 3/13/2024 | View on chart |
| ELV | ▼ Sell | Tax Withholding | 19,256 | $9.6M | 3/1/2024 | View on chart |
| ELV | ▲ Buy | Grant | 34,517 | $0 | 3/1/2024 | View on chart |
| ELV | ▲ Buy | Grant | 8,415 | $0 | 3/1/2024 | View on chart |
| TGT | ▲ Buy | Grant | 1,902 | $0 | 3/8/2023 | View on chart |
| ELV | ▼ Sell | Tax Withholding | 17,614 | $8.3M | 3/2/2023 | View on chart |
| ELV | ▼ Sell | Tax Withholding | 2,471 | $1.2M | 3/1/2023 | View on chart |
| ELV | ▲ Buy | Grant | 8,422 | $0 | 3/1/2023 | View on chart |
| ELV | ▲ Buy | Grant | 35,875 | $0 | 3/1/2023 | View on chart |
| ELV | ▼ Sell | Gift | 10,000 | $0 | 11/4/2022 | View on chart |
| TGT | ▲ Buy | Grant | 1,432 | $0 | 3/9/2022 | View on chart |
| ELV | ▼ Sell | Tax Withholding | 1,645 | $762K | 3/2/2022 | View on chart |
| ELV | ▼ Sell | Tax Withholding | 15,352 | $6.9M | 3/1/2022 | View on chart |
| ELV | ▲ Buy | Grant | 8,195 | $0 | 3/1/2022 | View on chart |
| ELV | ▲ Buy | Grant | 28,303 | $0 | 3/1/2022 | View on chart |
| TGT | ▲ Buy | Grant | 514 | $0 | 9/23/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Elevance Health Q3 Outlook: Premium Pressures and Sector Peer Trends
Elevance Health is preparing for its third-quarter earnings report, with analysts examining key metrics and the potential impact of lower premiums on the company's results. Broader sector news highlights peers like UnitedHealth, Centene, and Oscar Health pursuing growth and cost-saving strategies amidst shifting premium dynamics. The market is observing how these competitive and industry-wide pressures will align with Elevance Health's upcoming performance.
Elevance Health Q3 Outlook: Premium Pressures and Sector Peer Trends. Elevance Health is preparing for its third-quarter earnings report, with analysts examining key metrics and the potential impact of lower premiums on the company's results. Broader sector news highlights peers like UnitedHealth, Centene, and Oscar Health pursuing growth and cost-saving strategies amidst shifting premium dynamics. The market is observing how these competitive and industry-wide pressures will align with Elevance Health's upcoming performance.